Immune response of cancer patients against moulds

A HLA-DR coloured monocyte population of a patient suffering from a multiple myeloma compared with a sample from a healthy individual (Busch et al., Clin Exp Immunol 2014)
A HLA-DR coloured monocyte population of a patient suffering from a multiple myeloma compared with a sample from a healthy individual (Busch et al., Clin Exp Immunol 2014)

Cancer patients are known to have a reduced immune function. Previous work has described general aspects of alterations of the immune system (see figure). Currently, we are investigating the relevance of immune dysfunction with regard to the immune response against moulds.

Members
Kathleen Wagner

Dr. Kathleen Wagner

Susann Hartung

Dr. Susann Hartung

Post-doc

Phone: +49 3641 532-1061 Email: susann.hartung@leibniz-hki.de

Martin Föge

Dr. Martin Föge

Christopher Rauh

Christopher Rauh

Maria Schuwirth

cand. med.

Email: maria.schuwirth@uni-jena.de

Theresa Eifert

Bachelor student